Excuse me for interrupting, but...
I think people are extrapolating from that fact that, because 113, like Ponatinib, is the product of specific structural drug design(versus trial and error)by the same Ariad design team,
it will be just as successful as Ponatinib.
I, myself, believe this is highly likely, and that the Ariad team is at the forefront of a new design and development approach.
However, in conjunction with your specific question, no "we" don't have any proof of clinical efficacy of 113, strong or otherwise, to date.
But I think what we do have are various displays of institution confidence and support of late. And they may(probably do) know more(much more) than we do, in terms of the "winks and nods" that relate to 113 recent clinical activity.
Regards,
bw
